Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Myelofibrosis symptoms compromise health-related quality of life (HRQoL). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue ruxolitinib due to loss of response or unacceptable toxicity. Fedratinib is an oral, selective JAK2 inhibitor approved in the United States f...

Full description

Saved in:
Bibliographic Details
Published in:Hemasphere
Main Authors: Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Jourdan, Eric, Silver, Richard T., Schouten, Harry C., Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Tang, Derek, Abraham, Pranav, Lord-Bessen, Jennifer, Rose, Shelonitda, Guo, Shien, Liao, Weiqin, Mesa, Ruben A.
Format: Artigo
Language:Inglês
Published: Lippincott Williams & Wilkins 2021
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8096470/
https://ncbi.nlm.nih.gov/pubmed/33969275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000562
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items